Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status Prescription; Discontinued
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 38779-0191; 63622-0125; 63622-0123; 65044-7183; 51552-0304; 51927-1726; 45932-0008; 55500-0001; 63622-0124; 62991-1173; 62756-233; 39822-1055; 0469-3051
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiovascular disorder02.01.01.001; 24.03.02.009--Not Available
Cellulitis11.02.01.001; 23.09.01.001--Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.000412%Not Available
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.0010.000618%Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.0030.000412%Not Available
Chills08.01.09.001; 15.05.03.0160.001649%
Cholestasis09.01.01.001--Not Available
Coagulopathy01.01.02.001--Not Available
Coma17.02.09.001--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.0010.000824%
Cyanosis02.01.02.002; 22.02.02.007; 24.03.01.007--
Cystitis haemorrhagic20.03.02.003--Not Available
Deafness04.02.01.0010.000412%Not Available
Death08.04.01.0010.001129%
Dehydration14.05.05.001--
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000412%
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic07.02.01.002; 24.07.02.004--Not Available
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000161%
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Drug interaction08.06.03.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene